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Abstract: Word count 249 18 
Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium 19 
sulfate, is a triazole antifungal agent for the treatment of invasive fungal 20 
infections. The purpose of this analysis was to characterize the isavuconazole 21 
exposure-response relationship for measures of efficacy and safety in patients 22 
with invasive aspergillosis and other filamentous fungi from the SECURE trial. 23 
Two hundred and thirty one patients who received the clinical dosing regimen 24 
and had exposure parameters were included in this analysis. The primary drug 25 
exposure parameters included were predicted trough steady-state plasma 26 
concentrations, predicted trough concentrations after 7 and 14 days of drug 27 
administration, and area under the curve estimated at steady state (AUCss). The 28 
exposure parameters were analyzed against efficacy endpoints that included: all-29 
cause mortality through Day 42 in the intent-to-treat (ITT) and modified ITT 30 
population, data-review committee (DRC)-adjudicated overall response at end of 31 
treatment (EOT) and DRC-adjudicated clinical response at EOT. Safety 32 
endpoints analyzed were elevated or abnormal alanine aminotransferase, 33 
increased aspartate aminotransferase and the combination of both. The 34 
endpoints were analyzed using logistic regression models. No statistically 35 
significant relationship (P >0.05) was found between isavuconazole exposures 36 
and either efficacy or safety endpoints. The lack of association between 37 
exposure and efficacy indicates that the isavuconazole exposures achieved by 38 
clinical dosing were appropriate for treating the infecting organisms in the 39 
SECURE study and that increases in alanine or aspartate aminotransferase were 40 
not related to increase in exposures. Without a clear relationship, there is no 41 
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current clinical evidence for recommending routine therapeutic drug monitoring 42 
for isavuconazole.  43 
 4 
 
INTRODUCTION  44 
 The morbidity and mortality from invasive fungal diseases remain 45 
substantial (1). Triazole antifungal agents are first-line agents for the prevention 46 
and treatment of these infections. Voriconazole is recommended as primary 47 
treatment for invasive aspergillosis (IA). Posaconazole is primarily indicated as 48 
salvage therapy for patients with IA and prophylaxis for patients with neutropenia 49 
and hematopoietic stem-cell transplant recipients (2). Isavuconazole 50 
administered as the prodrug isavuconazonium sulfate, is a novel, broad-51 
spectrum, triazole antifungal agent. Recently, isavuconazonium sulfate has been 52 
approved by the US Food and Drug Administration for the treatment of adults 53 
with IA and invasive mucormycosis (3) and by the European Medicines Agency 54 
for the treatment of adults with IA and those with mucormycosis for whom 55 
amphotericin B is not appropriate (4). In the SECURE trial, isavuconazole was 56 
demonstrated to be non-inferior to voriconazole for the primary treatment of 57 
invasive mold disease caused by Aspergillus and  other filamentous fungi, as 58 
determined using all-cause mortality through Day 42 as the primary endpoint 59 
(19% vs.20%, respectively) (5). Overall response and clinical response rates 60 
were similar for isavuconazole and voriconazole (50% vs 47%, and 62% vs 60%, 61 
respectively), and the isavuconazole group had significantly lower rates of 62 
hepatobiliary disorders (9% vs 16%), eye disorders (15% vs 27%), skin or 63 
subcutaneous tissue disorders (33% vs 42%), and drug-related adverse events 64 
(42% vs 60%). 65 
 A deep understanding of the relationships between drug exposure and 66 
response is required to establish clinically useful threshold values for drug 67 
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exposure for both clinical outcomes and adverse events. Exposure-response 68 
relationships for efficacy are well established for other currently approved 69 
triazoles, such as itraconazole, posaconazole, and voriconazole, which has led to 70 
target drug concentrations that are necessary to maintain drug levels within safe 71 
and effective ranges (6-10). Exposure-response relationships for safety are also 72 
well established for itraconazole and voriconazole (8, 11). Thus, an important 73 
question remains as to whether these relationships are also evident for 74 
isavuconazole. Establishing clinically relevant exposure-response and exposure-75 
safety relationships will inform guidelines with respect to the potential need for 76 
therapeutic drug monitoring (TDM). 77 
In the SECURE trial, isavuconazole plasma concentrations were available 78 
for the majority of patients who were enrolled in the isavuconazole arm. 79 
Therefore, this post hoc analysis was conducted to evaluate the exposure-80 
response relationships in terms of efficacy and safety for isavuconazole using 81 
those patient data. Logistic regression modeling was used to explore the 82 
potential relationship between various measures of isavuconazole exposure, and 83 
both clinical outcomes and adverse events.   84 
 6 
 
MATERIAL AND METHODS   85 
Study design. SECURE (ClinicalTrials.gov identifier: NCT00412893) was a 86 
global, phase 3, randomized, multicenter, double-blind, parallel-group, non-87 
inferiority trial (Fig.1). Full details of the SECURE trial have been published 88 
previously (5). 89 
Patients with proven/probable disease, as assessed by an independent 90 
and blinded data-review committee (DRC), were included in the modified ITT 91 
(mITT) population. All patients received 372 mg of isavuconazonium sulfate 92 
(equivalent to 200 mg isavuconazole) administered by intravenous infusion (IV) 93 
every 8 hours for 6 doses (i.e., days 1 and 2), followed by a maintenance dose of 94 
372 mg isavuconazonium sulfate administered once daily, either IV or orally (PO), 95 
from Day 3 to end of treatment (EOT). Hereafter, only isavuconazole and the 96 
dosing equivalent will be used. 97 
 98 
Efficacy and safety assessments. In the current analysis, the efficacy 99 
endpoints included were (i) all-cause mortality through Day 42 in the ITT 100 
population and mITT populations (ii) DRC-adjudicated overall response at EOT in 101 
the ITT and mITT populations and (iii) DRC-adjudicated clinical response at EOT 102 
in the ITT and mITT populations. Liver function test values (aspartate 103 
aminotransferase [AST] and alanine transaminase [ALT]) at the EOT and post 104 
baseline (EOT + 10 days) were assessed as safety outcomes. 105 
 106 
Estimation of pharmacokinetic (exposure) parameters. A population 107 
pharmacokinetic model (PPK) was previously developed for concentration data 108 
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from the SECURE study in combination with data from healthy subjects, using 109 
NONMEM version 7.2 (GloboMax LLC, Hanover, MD, USA) (12). This publication 110 
lists values and dispersions associated with parameters that were used for the 111 
simulation. Total-drug area under the concentration-time curve at steady state 112 
(AUCSS) was calculated using the standard formula, AUC = F × dose/CL, based 113 
on the individual parameter estimates from the best PPK model, where F is 114 
bioavailability and CL is clearance. Individual parameter estimates obtained from 115 
the best model with covariates were used to calculate trough concentrations at 116 
steady state (Css), trough concentrations after 7 days of dosing (C7), and trough 117 
concentrations after 14 days of dosing (C14). 118 
 119 
Exposure-response analysis. All the efficacy and safety data were evaluated 120 
as binary and ordinal data using a logistic regression model in SAS® (version 9.3, 121 
SAS Institute Inc., Cary, NC, USA). The graphic processing of the data was also 122 
performed in SAS or R (Version 2.17, available at: https://www.r-project.org (13)). 123 
Each efficacy endpoint and safety endpoint as described above was analyzed 124 
separately using isavuconazole exposure parameters.  125 
The covariates were identified based on scientific interest or prior 126 
knowledge of any possible relationship with exposure parameters. Duration of 127 
therapy was the only continuous covariate investigated. Categorical covariates 128 
tested for the exposure-efficacy analysis included: race (Caucasian/Asian); 129 
hematological malignancy (yes/no); uncontrolled malignancy at baseline 130 
(yes/no); neutropenia at baseline (yes/no); serum galactomannan at baseline 131 
(<1/≥1); and lower respiratory tract disease (yes/no). Covariates along with 132 
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primary exposure parameters were added in an automated stepwise approach 133 
with α = 0.3 for model inclusion and α = 0.05 for model retention.  134 
Exposure-response analyses were also performed for patients in the ITT 135 
population who had minimum inhibitory concentration (MIC) values for any 136 
Aspergillus spp. (including A. flavus, A. fumigatus, A. niger, and A. terreus). MIC 137 
values were determined using the European Committee on Antimicrobial 138 
Susceptibility Testing (EUCAST) methodology (14) by Case Western Reserve 139 
University, Cleveland, OH, USA. AUC∞/MIC ratios were calculated based on 140 
model-predicted AUCss values for a patient and the corresponding highest MIC 141 
value, irrespective of the fungus that was cultured.   142 
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RESULTS 143 
Data for analysis. Two hundred thirty-one patients from a previously developed 144 
PPK model provided exposure parameters (12) used in the exposure-response 145 
analysis for both clinical outcomes and safety. One hundred twenty-nine patients 146 
qualified for the mITT population based on DRC-adjudicated criteria. A summary 147 
of the covariates used in this analysis is provided in Table 1.   148 
 149 
Exposure-efficacy analysis. Exposure parameters are summarized in Table 2. 150 
The mean calculated exposure at steady state (AUCss) was 101 mg*hr/L, with 151 
exposures ranging from 10 to 343 mg*hr/L. Mean trough concentrations at Css, 152 
C7 and C14 were approximately 3600 ng/mL, 2600 ng/mL, and 3000 ng/mL 153 
respectively. Trough concentrations ranged from 174 to 10,000 ng/mL. 154 
 155 
All-cause mortality at Day 42. All drug exposure parameters (i.e., AUCss, 156 
trough concentrations at Css, C7 and C14) were examined graphically and were 157 
modeled univariately. There was no apparent relationship between drug 158 
exposure parameters and mortality at Day 42 for either the ITT population or 159 
mITT population (Figure 2a and 2b, respectively). None of the primary 160 
parameters were retained in the logistic regression model. Logistic regression 161 
analysis did not suggest any positive association between exposure parameters 162 
and mortality at Day 42. Since none of the primary exposure parameters were 163 
retained in the model, further covariate analysis was not explored. 164 
 165 
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DRC adjudicated overall and clinical response at end of treatment (EOT). 166 
Graphical examination of binary outcomes for AUCss and Css for the ITT and 167 
mITT populations against clinical and overall response are shown in Fig. 3a and 168 
3b, respectively. Logistic regression models did not demonstrate any relationship 169 
of drug exposure with mortality, clinical response and overall response. None of 170 
the exposure parameters were significant at a significance level of 0.05 to be 171 
retained in the model. Similar results were obtained for C7 and C14 (data not 172 
shown). 173 
 174 
AUC/MIC calculations. There was only a small sample subset of patients with 175 
both PK parameters and pathogen susceptibility data available (n = 36) 176 
compared with the total number of subjects in this study.  Details of patients with 177 
MIC values are provided in the Supplementary Table S1.  No significant 178 
relationship (P>0.05) was identified between the AUC/MIC ratio and mortality at 179 
Day 42, the overall response at EOT, or the clinical response at EOT. Since only 180 
2 of the 36 patients were not included in the mITT population, that analysis would 181 
necessarily have yielded almost identical results and so it was not performed. No 182 
relationship was observed between MIC values and outcome parameters (15). 183 
 184 
Exposure-safety analysis. Patients with PK parameters used in the exposure-185 
response analysis were also included in this analysis. Graphical examination of 186 
binary outcomes for AUCss and Css for the ITT and mITT populations against 187 
normal/elevated levels of ALT and ALT are shown in Fig. 4. None of the primary 188 
exposure parameters were found to be statistically significant for any of the 189 
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safety outcomes (ALT or AST or combined ALT/AST) for either the ITT (n = 226) 190 
or mITT (n = 126) populations. As none of the primary exposure parameters were 191 
significant (P>0.3), there was no retention of parameters in the logistic model.  192 
  193 
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DISCUSSION  194 
The primary aim of this analysis was to investigate any potential 195 
relationship between various measures of drug exposure of isavuconazole and 196 
both efficacy and safety outcomes. Such an understanding is required to further 197 
reflect on the potential requirement for TDM as a component of routine clinical 198 
care of patients receiving isavuconazole. Conducting an exposure-199 
response/safety analysis provides an understanding of any threshold of exposure 200 
that is predictive of efficacy and/or adverse events.  201 
We were unable to demonstrate any statistically significant relationships 202 
for any measure of drug exposure (i.e., AUCss or Css or AUC/MIC) and various 203 
outcomes (i.e., all-cause mortality at Day 42 or clinical and overall responses at 204 
EOT or MIC of fungal isolates). A slight trend was observed for overall responses 205 
for both ITT and mITT populations, but this was not statistically significant (P > 206 
0.05). 207 
There could be several reasons for any lack of relationship between drug 208 
exposure and clinical outcomes from this analysis. Firstly, even though there 209 
were some extremes in predicted exposures, the variability was only 62% in 210 
patient population (12). Secondly, it is possible there was a degree of bias in the 211 
PPK model. The PPK model was fitted to data from both phase 1 and sparse 212 
data from phase 3 data. Even though there were 231 patients in the SECURE 213 
study, sparse data may potentially have led to biased estimates of exposure and 214 
Css values. However, there is no evidence of this given concordance with PK 215 
models fitted to other isavuconazole datasets (16). Poor compliance to the study 216 
drug could also have led to biased estimates of drug exposures, although there is 217 
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no specific evidence to suggest this occurred. Alternatively, assuming the 218 
existence of a sigmoidal exposure-response relationship, the lack of a 219 
relationship with outcomes might simply reflect that exposures were on the 220 
plateau of the curve (suprathreshold). The lack of association between exposure 221 
and response is consistent with the proposition that the isavuconazole exposures 222 
achieved by the clinical dosage regimen were near maximal for treating the 223 
infecting organisms in the SECURE study. In this respect, it is worth noting that 224 
the overall cure rate observed for isavuconazole in the SECURE trial was 225 
comparable to other trials of triazole antifungals (2, 5, 17, 18).  226 
 Although isolates were not obtained from the majority of patients (and 227 
therefore MIC values for the invading pathogens were not determined), it is likely 228 
that most patients were infected by wild-type organisms. It is possible that the 229 
inclusion of more patients infected with non wild-type strains might have enabled 230 
exposure-response relationships to be better described. In vivo and ex vivo 231 
models have demonstrated that the MIC values have a clear impact on 232 
exposure-response relationships, as proportionally higher drug exposures are 233 
required to achieve the same outcomes for strains with higher MICs (19-23). 234 
Although there were insufficient numbers of patients in the SECURE study for 235 
whom pathogen susceptibility was the only distinction to allow that possibility to 236 
be tested, a few patients with MIC values up to 8 mg/L were successfully treated 237 
(5). However, ongoing information from the post-license database may eventually 238 
enable clinical exposure-response relationships to be better defined.  239 
 Even though a threshold value for any drug exposure parameters was not 240 
found to be correlated with mortality and clinical response, the duration of 241 
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therapy did appear to be important and was statistically significant (P < 0.05). 242 
This finding should be interpreted with some caution. The importance of the 243 
duration of therapy may be confounded by other factors that influence outcomes 244 
(e.g., nature of the underlying disease). There is currently no definitive evidence 245 
that suggests that longer duration of therapy is necessarily associated with a 246 
better clinical response. Furthermore, there is no clear clinical evidence of the 247 
minimum duration of antifungal therapy that is required for clinical cure. 248 
Hepatotoxicity is a class effect for the azole group of antifungal agents 249 
with effects ranging from mild increase in liver function tests to possibly fatal 250 
hepatic failure being reported (24). The exact mechanism of elevated liver 251 
function with azole antifungal agents remains unknown (24). Due to the primary 252 
concern of elevated liver function values, exposure-safety analysis was 253 
performed on elevated ALT and AST levels. These values were available for all 254 
patients. The current analysis did not identify any association between 255 
isavuconazole exposure and elevated ALT or AST levels, or for a combination of 256 
both ALT/AST levels. One limitation of this analysis is the small proportion of 257 
patients who had elevated ALT or AST levels. Only 23/226 and 19/226 patients in 258 
this analysis had elevated ALT or AST levels.   259 
Voriconazole, posaconazole and itraconazole have target trough 260 
concentrations that need to be maintained in order optimize the probability of 261 
response. The voriconazole Cmin target recommended by the British Society of 262 
Medical Mycology is between 1.0 and 5.5 mg/L when the drug is used to treat 263 
invasive infection (7). The target voriconazole concentrations for prophylaxis is 264 
less clear. For posaconazole, the target trough concentrations are > 0.7 μg/mL 265 
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for prophylaxis and >1 mg/L for salvage therapy. For itraconazole, the target 266 
trough concentrations are similar to voriconazole (7). Fluconazole does not 267 
require routine therapeutic drug monitoring. There is no apparent relationship 268 
between exposure and efficacy to suggest routine TDM for isavuconazole. 269 
However, it is reasonable to continue observing real-world patients who are 270 
administered isavuconazole and monitor their exposures when necessary to 271 
ensure they do not require TDM. There might be a necessity to confirm 272 
isavuconazole exposures in select clinical cases (e.g. severe gut disease from 273 
graft-versus-host disease [in which drug absorption through oral route is 274 
problematic], in treatment of central nervous system infections, or in infections 275 
with non-wild type fungal pathogens). TDM may also be necessary when dosing 276 
in children or adolescents due to minimum exposure information (25). 277 
In conclusion, no statistically significant relationships were observed for 278 
any of the exposure parameters of isavuconazole (AUCss, Css, C7, and C14) 279 
with any safety markers (ALT, AST, and combined ALT/AST), either at the EOT 280 
or post baseline, nor with any efficacy endpoints (all-cause mortality, overall and 281 
clinical response). In some models, duration of therapy was retained in the model. 282 
However, this covariate is highly confounded making its relevance in this analysis 283 
unclear. Also, experimental PD models were conducted to establish the 284 
exposure-response relationship associated with efficacy and to estimate the 285 
target exposure associated with the optimal exposure-response relationship. The 286 
results showed that the clinical dosing regimen achieved exposures adequate to 287 
treat infections.  All models were developed on the observed data (12); however, 288 
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the model was not validated against external data from a clinical trial, which 289 
would have required performing additional isavuconazole studies.  290 
Finally, TDM may be considered for individual cases as discussed, but, at 291 
present, there is no clear evidence that there is a general need for TDM or a 292 
clear target in which to recommend. 293 
 294 
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Figure legends 420 
 421 
Fig 1 Study design 422 
 423 
BID, twice daily; EOT, end of treatment; IV, intravenous; QD, once daily; TID, 424 
three times daily. 425 
 426 
Fig 2 Box and whisker plots of drug exposure (AUCss and Css) vs mortality at 427 
Day 42 for ITT population (A) and mITT population (B) 428 
 429 
AUCss, total area under the concentration-time curve at steady state; Css, 430 
concentration at steady state; ITT, intent-to-treat; mITT, modified intent-to-treat. 431 
 432 
Fig 3 Box and whisker plots of drug exposure (AUCss and Css) vs clinical and 433 
overall response at EOT for ITT population (A) and mITT population (B) 434 
 435 
AUCss, total area under the concentration-time curve at steady state; Css, 436 
concentration at steady state; ITT, intent-to-treat; mITT, modified intent-to-treat. 437 
 438 
Fig 4 Box and whisker plots of drug exposure (AUCss and Css) vs ALT/AST 439 
levels at EOT for ITT population (A) and mITT population (B) 440 
 441 
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ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUCss, total 442 
area under the curve at steady state; Css, concentration at steady state; EOT, 443 
end of treatment; ITT, intent-to-treat; mITT, modified intent-to-treat. 444 
 445 
1 
 
TABLE 1 Summary of patient characteristics 1 
 2 
Patient characteristics ITT population (n = 231) mITT population (n = 129) 
 Yes  No  Yes  No  
Hematological malignancy 191 40 100 29 
Uncontrolled malignancy 156 75 79 50 
Neutropenia 150 81 79 50 
Elevated serum 
galactomannan at baselinea 
54 150 51 62 
Lower respiratory tract disease 182 49 104 25 
     
    
Duration of therapy (Median) 51 days 59 days 
Yes/No: Had/did not have characteristics at baseline. n is number of patients. aSome patients (n = 27) 3 
did not have galactomannan information at baseline. 4 
ITT, intent-to-treat, mITT, modified intent-to-treat. 5 
1 
 
TABLE 2 Summary of exposure parameters 1 
 2 
 AUCss 
(mg*h/L) 
Css 
(ng/mL)  
C7 
(ng/mL) 
C14 
(ng/mL) 
Mean (SD) 101 (56) 3633 (2023) 2631 (1033) 3049 (1397) 
Median 90 3218 2477 2923 
Range 10-343 174-10969 189-5627 174-7512 
Values rounded to nearest whole number. 3 
AUCss, total area under the curve at steady state; Css, concentration at steady state; C7, 4 
concentration after 7 days of dosing, C14, concentration after 14 days of dosing; SD, standard 5 
deviation. 6 
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IV or oral 200 mg QD
IV 4 mg/kg or oral 200 mg BID
Follow-up
28 days (±7)
after EOT2 3 42
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IV 200 mg TID
Isavuconazole
IV 6 mg/kg BID 
Voriconazole
IV 4 mg/kg BID
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FIG 1 Study design
Maximum therapy duration was 84 days.
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FIG 2 Box and whisker plots of drug exposure (AUCss and Css) vs mortality at Day 42 for ITT population (A) and
mITT population (B)
Boxes represent median, 25th and 75th percentiles; whiskers represent range of maximum and minimum values
within 1.5 × the interquartile range; outliers are shown as circles.
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FIG 3 Box and whisker plots of drug exposure (AUCss and Css) vs clinical and overall response at EOT for 
ITT population (A) and mITT population (B)
Boxes represent median, 25th and 75th percentiles; whiskers represent range of maximum and minimum values
within 1.5 × the interquartile range; outliers are shown as circles.
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FIG 4 Box and whisker plots of drug exposure (AUCss and Css) vs ALT/AST levels at EOT for ITT population (A)
and mITT population (B)
Boxes represent median, 25th and 75th percentiles; whiskers represent range of maximum and minimum values
within 1.5 × the interquartile range; outliers are shown as circles.
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